EGRIFTA (Tesamorelin)

EGRIFTA (Tesamorelin) 1mg / 1 Vial HGH Injection

0 out of 5

$60.00

Egrifta (tesamorelin) 1mg is specifically indicated for the reduction of excess abdominal fat in HIV-infected patients with lipodystrophy. This medicine is supplied as a sterile, white to off-white lyophilized powder for reconstitution designed for subcutaneous administration.

9223372036854775807 in stock

SKU: EGRIFTA Tesamorelin Category:HUMAN GROWTH HORMONES Tags:, ,
Compare

Description

Buy 1mg / 1 Vial EGRIFTA Tesamorelin HGH Injection Safely and Legally Online For HIV Patients from Powerall Pharmacy

What is EGRIFTA (Tesamorelin) HGH Injection?

Egrifta contains tesamorelin, an analog of human growth hormone-releasing factor (GRF). Tesamorelin binds and stimulates human GRF receptors with similar potency as the endogenous GRF. Growth hormone-releasing factor is a hypothalamic peptide that acts on the pituitary somatotroph cells to stimulate the synthesis and pulsatile release of endogenous growth hormone, which is both anabolic and lipolytic.

Egrifta is specifically indicated for the reduction of excess abdominal fat in HIV-infected patients with lipodystrophy.
Egrifta is supplied as a sterile, white to off-white lyophilized powder for reconstitution designed for subcutaneous administration. The recommended initial dose is 2 mg injected subcutaneously once a day. The recommended injection site is the abdomen. Injection sites should be rotated to different areas of the abdomen. So, Egrifta should not be injected into scar tissue, bruises, or the navel.

You should not take EGRIFTA if you:

  • have or have ever had any problems with your pituitary gland.
  • have cancer or are receiving treatment for cancer.
  • are allergic to tesamorelin or any of the ingredients in EGRIFTA®.
  • are pregnant or become pregnant. If you become pregnant, also stop using EGRIFTA® and talk with your healthcare provider.
  • are less than 18 years of age.

Before using EGRIFTA®, tell your healthcare provider if you

  1. have or have had cancer.
  2. have diabetes.
  3. are breastfeeding or plan to breastfeed.
  4. have kidney or liver problems.
  5. have any other medical conditions. also
  6. are taking any other prescription or non-prescription medicines, vitamins, or herbal supplements.
Side Effects of EGRIFTA (Tesamorelin)

Adverse events associated with the use of Egrifta may include, but are not limited to, the following:
-Arthralgia
-Injection site erythema
-Injection site pruritus
-Pain in extremity
-Peripheral edema, also
-Myalgia

Mechanism of Action

Egrifta contains tesamorelin, an analog of human growth hormone-releasing factor (GRF). Tesamorelin binds and stimulates human GRF receptors with similar potency as the endogenous GRF. Growth hormone-releasing factor is a hypothalamic peptide that acts on the pituitary somatotroph cells to stimulate the synthesis and pulsatile release of endogenous growth hormone, which is both anabolic and lipolytic. GH exerts its effects by interacting with specific receptors on a variety of target cells, including chondrocytes, osteoblasts, myocytes, hepatocytes, and also adipocytes, resulting in a host of pharmacodynamic effects.

STANDARD DOSE

2 mg via subcutaneous (under the skin) injection once daily in the abdomen, rotating injection sites and avoiding scar tissue, bruises, and the navel (see step-by-step video at egrifta.com and this page for more information).

Reviews

There are no reviews yet.

Only logged in customers who have purchased this product may leave a review.